Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
We report the case of a 57-year old female patient with refractory to treatment pyoderma gangrenosum associated with clinically inactive Crohn's disease. Pyoderma gangrenosum was successfully treated with Infliximab, a chimeric monoclonal antibody that inhibits tumour necrosis factor alpha (TNF-alpha). Our case report suggests that Infliximab, a therapeutic agent for refractory and fistulizing Crohn's disease, may also be safe and effective in the treatment of Crohn's disease associated pyoderma gangrenosum, even though the inflammatory bowel disease is clinically inactive and repeated infusions may be required for successful treatment.
Kouklakis
George
G
General Army Hospital, Thessaloniki, and Medical School Democritus University of Thrace, Alexandroupolis, Greece.
Moschos
John
J
Leontiadis
Grigoris I
GI
Kadis
Savvas
S
Mpoumponaris
Alexandros
A
Molyvas
Epaminondas
E
Minopoulos
George I
GI
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab